Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Education On-Demand: The Evolving Role of BTKi’s in CLL

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

Recorded June 28, 2022

The targeted therapy Bruton tyrosine kinase inhibitors (BTKi’s) have come a long way since revolutionizing CLL treatment with the arrival of ibrutinib. There are now other BTKi options such as acalabrutinib, zanubrutinib, and the next generation non-covalent BTK Inhibitor, pirtobrutinib. Join CLL Society and Dr. Matthew Davids from Dana Farber Cancer Institute to take a deep dive into different BTKi’s, how they work, how they compare to each other and other treatment options, potential side effects, and the future role of these therapies.


Robyn Brumble
Director of Scientific Affairs
CLL Society



Brian Koffman, MDCM (retired), MS Ed
Co-Founder, Executive Vice President, and Chief Medical Officer
CLL Society 


Matthew S. Davids, MD, MMSc
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana Farber Cancer Institute

This program was made possible by grant support from AstraZeneca, BeiGene, Pharmacyclics, and Janssen.